$4.48 $0.11 (2.5%)

11:12 AM EDT on 06/17/19

Ocular Therapeutix, Inc. (NASDAQ:OCUL)

CAPS Rating: 2 out of 5

Current Price $4.48 Mkt Cap $170.1M
Open $4.38 P/E Ratio 0.00
Prev. Close $4.37 Div. (Yield) $0.00 (0.0%)
Daily Range $4.29 - $4.52 Volume 64,327
52-Wk Range $2.36 - $5.00 Avg. Daily Vol.

Caps

How do you think NASDAQ:OCUL will perform against the market?

Add Stock to CAPS Watchlist

All Players

12 Outperform
3 Underperform
 

All-Star Players

1 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:OCUL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

TSIF (99.97)
Submitted February 17, 2016

Approval to do a Phase III is good news. First of TWO to start in two quarters and last....Meaning a long way to validate anything.I'm not a fan of a "sustained release" anything, but even if I were, based on their track record, however, despite the… More

NASDAQ:OCUL VS S&P 500 (SPY)

NASDAQ:OCUL Summary

Fools bullish on NASDAQ:OCUL are also bullish on:

Fools bearish on NASDAQ:OCUL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about OCUL.

Recs

0
Member Avatar OklaBoston (< 20) Submitted: 5/21/2019 7:14:55 PM : Outperform Start Price: $2.85 NASDAQ:OCUL Score: +52.10

Rising insider ownership plus having traded at more than 4 times this price in the past.

Recs

0
Member Avatar NoPlaceLikeHome (39.74) Submitted: 5/9/2017 4:15:50 PM : Outperform Start Price: $8.11 NASDAQ:OCUL Score: -67.12

This stock is under $250M market cap and has an approved drug ready to serve a several billion dollar market as soon as it fixes some manufacturing items. The risk/reward is too good to pass up.

Recs

0
Member Avatar ACave1 (< 20) Submitted: 4/6/2017 5:28:57 PM : Outperform Start Price: $8.12 NASDAQ:OCUL Score: -69.37

FDA approval expected in July for Dextenza eye insert for post-cataracts surgery to reduce swelling and pain. Recent clinical trial yielding very positive results. At an attractive price, Cowen and Company gave this a $60+ price target. FDA approval will give this stock a huge boost.

Leaderboard

Find the members with the highest scoring picks in OCUL.

Score Leader

HDTVBG

HDTVBG (< 20) Score: +302.55

The Score Leader is the player with the highest score across all their picks in OCUL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
OklaBoston < 20 5/22/2019 Outperform 3Y $2.85 +53.68% +1.58% +52.10 1 Comment
Ajormond 70.13 9/1/2017 Underperform 3Y $6.30 -30.48% +16.96% +47.44 0 Comment
WildShaman 93.71 7/5/2018 Underperform 5Y $6.53 -32.92% +6.54% +39.46 0 Comment
HDTVBG < 20 6/17/2019 Underperform 3W $4.38 0% +0.16% +0.16 0 Comment
thickheaded1 72.73 12/20/2017 Outperform 1Y $4.48 -2.23% +8.52% -10.75 0 Comment
jck444 92.70 12/10/2018 Outperform 5Y $5.81 -24.61% +10.10% -34.71 0 Comment
tenmiles 30.93 7/7/2017 Outperform 5Y $7.21 -39.25% +19.80% -59.05 0 Comment
HoyBoy < 20 8/5/2016 Outperform 5Y $5.89 -25.64% +33.50% -59.13 0 Comment
geneticbiscuit 58.89 1/24/2017 Outperform 3M $6.74 -35.01% +27.94% -62.95 0 Comment
NoPlaceLikeHome 39.74 5/10/2017 Outperform 3Y $8.11 -45.99% +21.13% -67.12 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OCUL.

Advertisement